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Abstract
Patients with alcohol use disorders (AUDs) are frequently treated with antidepres-
sant drugs (ADs), but clinical evidence of their efficacy is contradictory. Considering 
that ADs are thought to produce their therapeutic effects partially by increasing 
hippocampal plasticity and neurogenesis (HN), and that both AUDs and depression 
share a potential for the disruption of these neuroplastic processes, one could reason-
ably wonder whether the poor efficacy of AD treatment could be explained by the 
inability of these drugs to exert their proper action in patients suffering from AUD 
or depression. In order to further clarify this question, this chapter aims to examine 
available data regarding the effect of ADs on behavioral and HN alterations related to 
alcohol abstinence, as a key period in which the treatment would be implemented and 
in which their potential effects on alcohol-related problems remain under controversy.
Keywords: alcohol use disorders (AUDs), antidepressants (ADs),  
hippocampal neurogenesis (HN), depression, comorbidity, alcohol withdrawal
1. Introduction
AUD is a chronic relapsing brain disease characterized by the presence of various 
symptoms, such as physically hazardous alcohol drinking, tolerance, withdrawal, 
or craving related to alcohol consumption, whereas MD is a psychiatric disorder 
characterized by low mood, anhedonia, insomnia, low motivation, apathy, and 
feelings of guilt, among other symptoms [1]. Epidemiological studies have shown a 
strong relationship between alcohol use disorders (AUDs) and depression. Indeed, 
the prevalence of current or lifetime alcohol problems in depression is estimated 
around 16% and 30%, respectively [2].
Adult hippocampal neurogenesis (HN) is a complex multistep process by which 
neural progenitor cells (NPCs) divide throughout life and give rise to new functional 
neurons in restricted regions of the adult mammalian brain (Figure 1, and also 
described in [3]). The dentate gyrus of the hippocampus is one of the brain areas 
that respond to stimuli through multiple mechanisms that allow the proliferation, 
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maturation, and integration of new generated neurons in this structure, an event that 
appears to regulate and improve impaired cognition and mood in various disorders [4]. 
Both AUDs and depression have shown to compromise HN processes [5, 6]. The HN 
theory of depression sustains that depression results from impaired adult HN, and, 
therefore, its restoration leads to recovery [7]. Direct causality of HN alterations in 
the pathogenesis of depression seems unlikely [8], but the clinical relevance of hip-
pocampal newly generated neurons in depression continues to be the object of study 
[9]. In addition, HN and plasticity processes have been proposed as a possible common 
neurobiological mechanism underlying alcohol withdrawal and depression [10]. In 
fact, HN has been proposed to significantly contribute to alcoholic pathology, although 
the mechanisms of alcohol-induced alterations in HN are not completely understood 
[6]. In this sense, there is strong evidence in animal models that alcoholic neuropathol-
ogy is at least partially due to an attenuation of adult HN induced by intoxication, a 
state that could be reversed by spontaneous reactive HN processes during abstinence 
[11]. In this regard, authors have proposed that while suppression of hippocampal 
neurogenic proliferation appears to be a factor of comorbid vulnerability, enhancing 
HN into the neural circuits affected by drug may contribute to recovery [12, 13].
Antidepressants (ADs), mainly selective serotonin reuptake inhibitors (SSRIs) 
and tricyclic antidepressants (TCAs), are the primary pharmacological treatment 
indicated for depression-diagnosed patients [14]. Concurrently, evidence of mono-
amine alterations in AUDs has encouraged the investigation of drugs that act on the 
serotonin system to treat alcohol abuse [15]. Only a few drugs with clear evidence 
but modest effects are approved for treatment of AUDs, as naltrexone and acam-
prosate, although given certain clinical circumstances, substance use disorders may 
require specific treatment; thus, off-label medications like ADs are also frequently 
prescribed, mainly in AUD depressed patients [16]. At first, the monoamine theory 
of depression is based on the fact that brain monoamine systems appear to regulate 
mood and traditional ADs, such as SSRI, and selectively increase monoamine signal-
ing in neural pathways related to mood regulation [17]. Later, at the beginning of the 
century, different results supported the hypothesis that ADs might affect mood by 
increasing adult HN [18]. At the same time, numerous studies have led to propose 
that ADs can influence HN by serotonin modulation and that HN may be related 
to AD effects (reviewed in [19]). In agreement, postmortem studies have reported 
Figure 1. 
Schematic representation of the stages of adult hippocampal neurogenesis in the subgranular zone of the 
dentate gyrus and the main immunolabeling techniques used in the cited studies.
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that ADs augment NPC numbers [20, 21] and restore mature hippocampal neural 
population and dentate gyrus volume of depressed patients [22, 23]. These human 
data reflect the neurogenic potential of ADs previously reported in animals [24]. In 
this respect, animal studies have led to suggest that, while not causally involved in 
the onset of depression, HN has been related to the ability of chronic monoaminergic 
ADs to achieve recovery [8]. Recent studies have reopened the debate about the 
functional implication of adult HN in humans (see [25]), highlighting the need to 
further study the generation of new neurons in the adult human hippocampus. This 
also implies to characterize the role of HN in depression and AUDs [4, 6] and the 
extent to which it participates in recovery in the treatment with ADs [26].
2. Alcohol use disorders and depression
Data from AUD patients have led to the proposal that the effective components of 
withdrawal, such as dysphoria and depressed mood, create a motivational drive that 
leads to compulsive ethanol drinking behavior even after long periods of abstinence [27]. 
Subsequent findings promoted the hypothesis that drugs of abuse elicit pronounced 
euphoria followed by a negative emotional state that can disrupt homeostasis, considered 
key to the etiology and maintenance of the pathophysiology of addiction [28].
2.1  Clinical and preclinical evidence of AUD contribution to depressive 
symptomatology
Authors have considered whether there may be a causal relationship between 
AUDs and depression and whether one of the disorders can lead to the appear-
ance of the other. Thus, numerous studies reveal ample evidence of the risk of 
depression resulting from AUDs [29]. Moreover, problematic patterns of alcohol 
consumption are related to depressive symptomatology, both in adult and ado-
lescent populations [30, 31]. In an attempt to simplify the complexities of the 
relation between AUDs and depression, a classification of depression as primary or 
secondary according to whether it developed before or after the onset of the AUD 
was proposed. The term independent (ID) was used for a depression that began 
before the onset of alcohol dependence or during sustained (at least 4 weeks) 
abstinence, while depressive syndromes occurring only during a period of active 
alcohol dependence were labeled as substance-induced (SID) [32]. However, some 
of the depressive symptoms classified as ID could actually be substance-induced, 
as SID appears not to be a stable diagnosis, with about one quarter of patients 
initially labeled with SID meeting criteria for ID within the next 12 months [33]. 
Thus, SID would be considered a self-limiting condition that would tend to remit 
with abstinence, while ID would require specific depression treatment [32]. After 
receiving treatment for alcohol consumption, those with SID would show better 
depression outcomes and reduce their drinking more than those with ID [32]. 
Also, and further supporting a causal role of alcohol consumption in depression, 
reducing its consumption would improve the outcomes for both types of depres-
sion [34]. In the same sense, some authors have proposed that reducing hazardous 
drinking can improve depressive symptoms, but continued hazardous use slows 
recovery for psychiatric patients [35].
2.2 Preclinical evidence of the contribution of alcohol to depressive-like behavior
Animal studies might overcome the limitations of the clinical studies, allowing 
to obtain not only correlative information but also contributing data that would 
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allow a larger approach to the possible underlying causes in the relation of the AUD 
and depression. Several preclinical studies have assessed behavioral alterations 
during acute withdrawal and/or protracted abstinence in different animal models 
of alcohol abuse [36–47]. Studies used rodents as experimental animals, and the 
majority used the AUD model of chronic intermittent ethanol (CIE) vapor expo-
sure. Behavioral analysis was carried out from a few hours (less than 24 hours) to 
several days or weeks after the last alcohol consumption, using the forced swim-
ming test (FST) the most frequently used paradigm for this purpose. FST allows 
detecting responses toward an inescapable stress in animals based on the measure-
ment of the time they remain immobile rather than displaying active strategies, 
akin to responses that would be impaired in depression. This response has been 
commonly described in the literature as depressive-like behavior. Affective altera-
tions induced by alcohol were generally detected once alcohol exposure ceased, 
regardless of the animal model used, with few exceptions. It is interesting to 
note that studies evaluating both acute and chronic abstinence found occurrence 
of depressive-like behavior in both experimental periods although mostly after 
prolonged abstinence, which may indicate that the negative affective state as a 
consequence of abstinence, especially when maintained for prolonged periods, 
might be a risk factor for displaying depressive-like behavior, analogous to the way 
in which depression manifests itself in abstinent AUD patients.
2.3 Depression contributes to the risk of alcohol relapse
As previously mentioned, a negative affective state is not only a consequence of 
consumption but also could represent a maintenance factor for the addiction cycle 
[28]. In coherence, the “self-medication” theory postulates that the desire to avoid 
or alleviate preexisting or abstinence-related aversive states is a determining fac-
tor of excessive drug use and relapse [48]. Relapse is one of the most complicated 
components of drug addiction and involves a complex interaction of drug-associated 
cues that respond to multiple biological, psychiatric, psychological, and psychosocial 
factors which may precipitate the restoration of consumption [49, 50]. Therefore, 
one of the main goals in treating substance abuse is to preserve abstinence.
2.4  Clinical evidence of depressive symptomatology contributing  
to the risk of alcohol relapse
Clinical data strongly support the relevance of negative emotionality in protracted 
abstinence and relapse. Thus, for example, a higher prevalence of depressed mood has 
been observed in AUD patients who relapsed [51]. Depression-related low motiva-
tion has been shown to precipitate alcohol relapse, while improvements contributed 
to greater abstinence [52–55]. In fact, those studies have emphasized the need to treat 
depression to preserve abstinence and improve outcome of patients with AUD. We men-
tioned before that the AUD can contribute to an ID or a SID. Thus, some authors wonder 
whether transient symptomatology (SID) would affect consumption in the same way as 
the observed ID in prolonged abstinence. In this sense, it has been suggested that while 
affective dysregulation in protracted abstinence is likely to be of immediate relevance for 
relapse to excessive alcohol use, the link between the early withdrawal phenomena and 
subsequent affective alterations remains unclear. However, other authors have concluded 
that both categories should be taken into account as factors that would precipitate 
relapse. Specifically, SID has been associated with a shorter time for the first alcohol con-
sumption after discharge, while ID, in addition, predicted relapse to alcohol dependence. 
Interestingly, ID prior to the AUD did not predict outcomes for patients [56].
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2.5  Preclinical evidence of depressive-like behavior contributing  
to the risk of alcohol relapse
Results from clinical studies underline the need to understand possible underly-
ing factors that contribute to the mutual negative influence of both pathologies. In 
this sense, animal models of AUD and depression offer the possibility of elucidating 
potential factors involved in the development of dual disorders [57]. Despite the 
prevalent comorbidity between depression and AUDs, direct evidence of causal-
ity of co-occurrence of the two pathologies is still scarce. Thus, Riga et al. [58] 
used a combination of models of depression and AUD through social defeat and 
alcohol self-administration and reported that a persistent depressive-like state led 
to profound alcohol reward-related changes, exaggerating the incentive salience of 
alcohol and facilitating cue-induced relapse to alcohol seeking. In addition, Lee et al. 
[47] reported higher alcohol self-administration behavior in mice which exhibited 
depressive-like behavior in prolonged abstinence as consequence of alcohol self-
administration. It is interesting to note that this condition only occurred in animals 
that were exposed to alcohol during their adolescence and not in those in which the 
first exposure took place during adulthood, and that did not show alcohol-related 
affective alterations. Animal studies would show that affective alterations that 
persist in prolonged abstinence, regardless of whether they were related or not 
with alcohol exposure, would increase self-administration behavior under alcohol 
re-exposition.
3. Alcohol use disorders and hippocampal neurogenesis deterioration
Years ago, the proposal arose that alcohol abuse might exert its negative effect 
in the human brain through an induction of neuronal loss on the hippocampus. In 
agreement, animal models of chronic alcohol exposure have shown consistently that 
alcohol is toxic to hippocampal neurons, inducing cell loss. Subsequent studies have 
led to suggest that alcohol may result in hippocampal pathology and deterioration 
through effects on adult HN (see [6]).
3.1  Clinical evidence of AUDs contributing to hippocampal  
neurogenesis deterioration
The lack of techniques to assess adult HN in vivo in AUD patients limits the 
available information in this regard essentially to postmortem or neuroimaging 
studies. To date, we have only found one study that has shown that alcohol would 
have a negative effect on HN in humans [59]. Authors reported reduced numbers 
of three biomarkers representing different stages of the HN process: Ki67, as 
marker for cell proliferation, the sex determining region Y-box (Sox2) as stem/
progenitor cell marker, and doublecortin (DCX) as marker of neural matura-
tion in the dentate gyrus in subjects with ongoing alcohol abuse. These results 
converge with previous findings in human with a history of drug abuse [60]. 
Otherwise, neuroimaging studies allow the detection that alcohol abuse could 
also impair hippocampal volume. Indeed, some studies have revealed decreases in 
hippocampal volume in AUD patients, although these changes have been shown to 
revert with abstinence (reviewed in [61]). There is also evidence of impairment in 
hippocampus-related functions as consequence of problematic alcohol consump-
tion, effects that, similarly to those found in volumetric studies, could improve 
with abstinence [62].
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3.2  Preclinical evidence of alcohol contributing to hippocampal  
neurogenesis deterioration
Animal studies are useful to compensate for the limited clinical evidence in AUD 
patients. In fact, the most consistent evidence of alcohol-induced hippocampal impair-
ment due to, in part, its action on HN comes from preclinical studies. In addition, the 
different immunolabeling techniques allow us to differentiate the stages of adult animal 
HN, as proliferation, maturation, migration, and survival of newly generated cells. 
Obtaining samples throughout different stages offers detailed information on how these 
processes are altered along the addictive cycle, which constitutes a great advantage 
over the limitations of postmortem studies in humans. The majority of in vivo stud-
ies have shown that alcohol intoxication leads to an overall decrease in HN through 
alcohol’s effects on cell proliferation and survival [63], while those HN parameters 
show heterogeneous results when assessed throughout abstinence. Several animal 
studies have evaluated HN parameters along acute withdrawal and/or protracted 
abstinence in different AUD models. Studies mainly analyzed parameters of HN at 
different times throughout abstinence and reported increases, decreases, and mixed 
results in HN-related parameters [64–79]. Studies were mainly in rodents (except [72], 
done in nonhuman primates). A large part of the studies used a 4-day binge model or 
self-administration protocols, whereas few authors used the CIE vapor exposure model. 
Different immunolabeling techniques have been used to assess HN in animals, mainly 
the thymidine analogue bromodeoxyuridine (BrdU), which is incorporated into divid-
ing cells and allows monitoring of newly generated neurons in the adult brain. Main 
relevant aspects of results from those studies are analyzed in detail in the conclusion.
3.3  Hippocampal neurogenesis deterioration contributes to the risk  
of alcohol relapse
Hippocampus is essential in consolidation of stimuli previously paired with 
drug intake, and authors have proposed that alcohol produces strong deficits 
in hippocampus-dependent learning and memory and attenuates hippocampal 
plasticity during withdrawal, which may motivate attempts to self-medicate result-
ing in relapse and maintenance of drug use [80]. In this sense, one way by which 
impaired HN could contribute to addiction would be by disrupting learning and 
memory and by inducing negative affective states, both factors increasing suscepti-
bility to relapse [81]. On the other hand, research during the last decade has shown 
that it is possible to disrupt alcohol-induced cues and that this has a lasting impact 
in reducing the tendency to seek drugs and to relapse [82]. In this regard, authors 
have suggested that although there are a host of plastic changes that occur with 
abstinence, one way that the hippocampus may recover in abstinence is through the 
repopulation of the dentate gyrus by adult HN [6].
3.4  Clinical evidence of hippocampal neurogenesis deterioration  
contributes to the risk of alcohol relapse
In the same way as in the previous sections, human studies provide indirect 
indicators of the role of HN, such as the volume and functionality of the hippocam-
pus. In this regard, clinical studies found that deficits in hippocampal volume in 
AUD patients compared with healthy controls normalize over an abstinence period 
of 2 weeks [83] and that hippocampal volume did not constitute a predictive factor 
for relapse risk in abstinent alcoholics [84]. On the other hand, it has been observed 
that the hippocampal-dependent functions could continue to be altered even in 
prolonged abstinence [62], which could be a factor that, as other authors propose, 
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would alter cognitive aspects linked to the risk of relapse [80]. Information from 
clinical studies shows that the course of the AUD would be related to the func-
tionality of the hippocampus and not so much with alterations in its structure. 
Unfortunately, like the previous section, we are faced with a lack of clinical evi-
dence in this regard, since we do not have information on the role that newly gener-
ated neurons in the hippocampus would play on the learning and memory processes 
involved in prevent relapse.
3.5  Preclinical evidence of hippocampal neurogenesis deterioration  
contributes to the risk of alcohol relapse
Numerous animal studies have led to suggest that low neurogenic states 
could regulate the addictive behavior, assuming a factor of addiction or comor-
bid vulnerability [12]. Specifically, animal models of drug addiction studies 
have led to propose that adult HN appears to be important for the maintenance 
of hippocampal neuroplasticity, such that reducing HN during abstinence may 
increase the vulnerability to relapse, while enhancing HN during abstinence 
may help reduce the risk of relapse [22]. Among the studies cited that assessed 
HN parameters, only one study [78] analyzed the levels of alcohol consump-
tion after the period of abstinence. Thus, they reported augmented alcohol 
self-administration after 4 weeks of abstinence in animals that showed reduced 
HN at the end of the experiment as consequence of a combination of self-
administration and vapor exposures to alcohol (dependent animals) compared 
to animals that showed no reductions in HN who did not receive exposure to 
vaporized alcohol (nondependent animals). Some results from [78] suggest 
that the observed reactive HN effect does not have an implication in recovery. 
On the contrary, animals that showed this reactive effect and lower levels of 
survival of newly generated neurons ended up showing higher alcohol con-
sumption during relapse. Main implications of these findings are analyzed in 
the conclusion.
4.  AD treatment in alcohol use disorders, depression,  
and hippocampal neurogenesis
Several studies have led to the suggestion that reversing depressive symptom-
atology [54] and HN deterioration [21] could be a therapeutical option in cases of 
comorbidity between AUDs and depression. Given the potential of ADs to improve 
affective symptoms and promote HN, it is reasonable to assume that such treatment 
would benefit AUD patients. The following sections attempt to clarify these aspects.
4.1  Clinical evidence of antidepressant treatment improves depressive 
symptomatology and hippocampal neurogenesis deterioration
Meta-analysis and reviews that integrate results of clinical studies in which 
patients with AUD and depression were treated with ADs show drug-dependent 
and inconclusive results. Some findings showed that SSRIs adequately treat 
depressive symptomatology in individuals with AUD and depression [85–87], 
while others showed that SSRIs were not more effective than placebo in treating 
comorbid patients [88, 89]. In relation, it has also been seen that SSRIs would not 
show greater effects than TCAs [90]. In fact, results from different studies using 
TCAs seem to converge in its effectiveness in alleviating depressive symptom-
atology [88, 91]. This may present differences in the response to a treatment for 
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depression in alcohol-dependent participants depending on the different types of 
depression, as a stronger effect of ADs was found in ID than in SID patients [32]. 
The most recent meta-analysis available concerning the efficacy of AD treatment 
in these patients shows a modest effect in some outcomes of depression [92]. 
However, most authors point out the need for more studies with similar outcome 
measures, well-defined sample designs, adequate doses, and duration of treat-
ment so that the integration of studies can reach conclusions with a high quality of 
evidence [87, 90, 92], and some of them emphasize the need to evaluate possible 
alternative ADs, as, for example, nonselective or partial agonist-reuptake inhibi-
tors [93, 94]. On the other hand, as seen in the introduction, ADs have shown to 
potentially increase HN in depressed patients [20, 21]. Unfortunately, no evidence 
of AD-related HN effect has been described in AUD patients.
4.2  Preclinical evidence of antidepressant treatment improves  
depressive-like behavior and hippocampal neurogenesis deterioration  
in alcohol exposure and abstinence
Studies in animals have suggested that the ability of AD treatment to affect HN 
would be linked to its behavioral therapeutic effects [8]. In fact, authors reported that 
increasing HN has been demonstrated to be necessary and sufficient to reduce depres-
sive-like behavior in animals [95]. On the contrary, other authors have concluded 
that, although ADs promote HN, this would not be a critical event for their mood-rec-
tifying actions [96]. In the same direction, authors have proposed that the therapeutic 
effect of the AD would not be determined exclusively by an increase in the number of 
newly generated neurons but rather in the way in which those neurons are function-
ally incorporated into hippocampal preexisting circuits that would be linked to recov-
ery [97]. Few animal studies evaluated the efficacy of an AD treatment (desipramine, 
imipramine, and amitifadine) in a model of alcohol exposure. Studies from Getachew 
et al. [36, 43] found that subchronic desipramine and imipramine treatment reversed 
depression-like behavior and anxiety in rodents under acute withdrawal conditions. 
Similarly, Warnock et al. [39] reported that two different doses of acute amitifadine 
reversed the abstinence-induced increased immobility in the FST. Finally, Stevenson 
et al. [37] reported that subchronic desipramine reverted depression-like behavior 
and restored HN parameters, both aspects impaired under protracted abstinence 
conditions in mice. Similarly, other studies have tested the efficacy of AD-like drugs 
as 7,8-DHF, a trkB agonist [40]; trichostatin A, a histone deacetylase inhibitor [76]; 
rolipram, a phosphodiesterase-4 inhibitor [45]; or ketamine, a N-methyl-D-aspartate 
receptor antagonist [42, 46], reporting that those treatments also restored the HN 
parameters and/or the behavioral alterations impaired by the exposure and absti-
nence to alcohol. In addition, non-pharmacological conditions, as wheel running 
or natural extracts, induced similar patterns of recovery in HN parameters [65, 77] 
and in depressive-like behavior [45, 50] in rodents exposed and abstinent of alcohol. 
This data, in conjunction with previous studies that used ADs, would suggest that if 
a treatment had protective effects on the NH function, it could also reflect its thera-
peutic effect on affective disturbances in alcohol exposed animals. Nevertheless, the 
causality of this relationship needs to be further elucidated. Figure 2 illustrates the 
possible state and role of HN during alcohol withdrawal.
4.3  Clinical evidence of antidepressant treatment improves depressive  
and alcohol use disorder outcome
Although ADs are not among the first-line treatment options in AUD, they are 
among the additional alternative treatments available, mainly when comorbid 
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conditions are present [16]. In this regard, authors have proposed that AD treat-
ment could ameliorate alcohol consumption [98], possibly by improving depressive 
symptoms [99]. Some of the aforementioned studies and meta-analysis evaluated 
alcohol-related outcomes in AUD depressed patients [87, 90, 92], showing a modest 
or no efficacy of AD treatment in alleviating some aspects linked to alcohol con-
sumption. Recent conclusions show that ADs increased the number of participants 
abstaining during the trials and reduced the number of drinks per drinking day, 
while no differences were reported between ADs and placebo in other relevant out-
comes of the AUD [92]. In addition to the mentioned low overall effectiveness, it is 
important to mention that some studies reported even poorer drinking outcomes in 
AUD patients treated with SSRIs compared to those treated with placebo [100–102]. 
In this line, studies have reported clinical cases where treatment with SSRIs appears 
to be the cause of increased frequency of intoxication by alcohol and new onset of 
alcohol-related problems [103–105]. Finally, patients who actively drink suffering of 
comorbid anxiety and AUD have also shown that they may increase alcohol con-
sumption under treatment with SSRIs [106].
4.4 Preclinical evidence of antidepressant treatment improves alcohol relapse
Preclinical data concerning the effectiveness of pharmacological treatments 
in AUDs is still scarce [107]. Animal studies that evaluate the effect of different 
AD treatments on preventing alcohol consumption report reduction in alcohol 
intake after an acute drug dose or under short-term relapse conditions [108]. 
Nonetheless, taking in mind that the evaluation of the effectiveness of conven-
tional AD treatment should be done considering the delay in its therapeutic 
effects, studies should go beyond short-term evaluations, assessing long-term 
Figure 2. 
(a) Schematic representation of the adult HN along alcohol withdrawal and abstinence. Spontaneous burst in 
cell proliferation is followed by a lower survivability and aberrant patterns of cell migration and integration of 
the newly generated neurons which could contribute to vulnerability related circuitry. (b) Exogenously induced 
cell proliferation (by physical exercise or proneurogenic treatment as ADs) could prevent the consolidation 
of neural circuitry involved in vulnerability, promoting survivability and integration of the newly generated 
neurons into neural pathways of recovery.
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consequences of treatment in animal models that better mimic AUD patient 
conditions [109]. Thus, unlike studies using acute treatments, authors that 
evaluated chronic and subchronic escitalopram, sertraline, paroxetine, fluox-
etine (SSRIs), and duloxetine, dual serotonin/norepinephrine reuptake inhibitor 
(SNRI) treatments found that, along the treatment period, animals showed 
lower alcohol intake levels, but cessation of treatment produced a restoration of 
basal alcohol consumption [110–112]. Ho et al. [110] also found an augmentation 
in alcohol intake in depressed animals once treatment with escitalopram ceased. 
Interestingly, authors also found the same effect in animals under combina-
tion of AD (escitalopram) and anti-relapse (acamprosate) treatments. Related 
to that, subchronic treatment with different ADs (SSRIs and SNRIs) has been 
demonstrated to augment alcohol consumption in animal models of alcohol 
deprivation, which were treated along abstinence and re-exposed to alcohol self-
administration once AD treatment ended [113, 114].
5. Conclusions
Translating evidence from preclinical studies to clinical practice still creates 
a major challenge in development of new pharmacological treatments in AUDs. 
The first thing we must point out is the lack of animal studies that have evaluated 
the effectiveness of the AD treatment in alcohol exposure and abstinence. In this 
sense, it is important to highlight the numerous studies in animals that evaluate the 
alcohol exposure and abstinence impact on affective and HN parameters compared 
to the scarce studies that try to reverse such effects by testing appropriate ADs. In 
addition, strong criteria are needed when evaluating treatments in AUD animal 
models, highlighting the use of self-administration procedures and the evaluation 
of dependence by observing abstinence and relapse behavior. In this sense, animal 
studies evaluating HN alterations were mainly used as short periods (4 days) of 
forced alcohol exposition, while prolonged self-administration or CIE models, 
which better represent important aspects of alcohol consumption patterns in AUD 
patients, were used to a lesser extent.
One of the most direct methodological limitations when comparing clinical and 
preclinical studies is determined by the period in which the AD treatment begins. 
Preclinical studies would indicate that animals can display different affective 
responses to ADs according to the moment it is administered. In addition, AD ces-
sation could have negative repercussions in alcohol consumption and relapse. While 
these effects should be further clarified in future studies, clinical trials should take 
these relevant aspects into account.
The debate about the implication of the new neurons generated in the hippo-
campus as a consequence of alcohol abstinence continues to be an object of interest. 
Despite alcohol-induced HN impairments that mainly persist along abstinence, 
some studies have shown increases in parameters of neural proliferation in animals 
mainly along early withdrawal periods. First, the possible role of this HN re-
establishment effect as factor of recovery was considered, but later studies would 
even point to opposing hypotheses. In this regard, other findings led to the question 
whether neurons born during this reactive neurogenic process survive or properly 
integrate into the existing hippocampal circuitry to provide beneficial effects on 
hippocampal function and recovery. An early increase in neuronal proliferation 
induced by abstinence, followed by a reduction in survival in prolonged abstinence, 
appears to result in an increase in alcohol self-administration. Thus, this apparent 
AD-induced dual role of HN and the consequent changes in addictive behavior 
should be elucidated.
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To resume, preclinical evidence strongly supports that alcohol consumption 
and abstinence lead to negative affective states and alterations in HN, some of 
which may persist in prolonged abstinence. Although affective alterations related to 
alcohol have been evaluated, there is limited data available concerning the alcohol-
induced HN deterioration in clinical patients. Both alcohol-induced depression 
and changes in HN could be relevant to promote relapse, exacerbating the addic-
tive cycle, although additional studies should clarify this complex interaction. 
Conventional ADs have been proposed to alleviate affective alterations possibly 
by promoting HN; thus AUD depressed patients could benefit from its effects. 
Unfortunately, clinical trials still face several limitations in order to draw reli-
able conclusions in this regard. Moreover, preclinical studies should bear in mind 
important methodological aspects onward when translating information regarding 
the efficacy of AD treatment into AUD patients.
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